Figure Technology Solutions Inc. Class A Common Stock vs Cassava Sciences Inc — how do they compare? Figure Technology Solutions Inc. Class A Common Stock trades at $28.12 (market cap $6.19B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Figure Technology Solutions Inc. Class A Common Stock is far larger — about 157.1× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 4,762,342). Which is the better fit depends on your goals — on Pluang, investors hold Figure Technology Solutions Inc. Class A Common Stock for 0 Days and Cassava Sciences Inc for 37 Days on average.
| FIGR | FLNA | |
|---|---|---|
Market Cap | $6.19B | $39.40M |
Volume | 4,762,342 | 759,018 |
Sector | Financials | Health |
52-Week High | $73.91 | $4.64 |
52-Week Low | $24.91 | $0.68 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $6.23B | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.
Read more on FIGR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →